KR860001471B1
(ko)
|
1980-04-03 |
1986-09-26 |
비오겐 엔. 브이 |
인체의 섬유아세포 인터페론(IFN-β)폴리펩티드의 제조방법
|
IT1185503B
(it)
*
|
1984-01-11 |
1987-11-12 |
Univ New York |
Cloni di odna di eritropietina umana
|
JPS62501010A
(ja)
|
1984-12-04 |
1987-04-23 |
ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド |
エリトロポエチンの生産方法
|
IL77081A
(en)
*
|
1984-12-04 |
1999-10-28 |
Genetics Inst |
AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
|
US4677195A
(en)
*
|
1985-01-11 |
1987-06-30 |
Genetics Institute, Inc. |
Method for the purification of erythropoietin and erythropoietin compositions
|
US4745099A
(en)
*
|
1985-02-06 |
1988-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for the treatment of the anemia of malignant tumors
|
US4732889A
(en)
*
|
1985-02-06 |
1988-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
|
GB2177914B
(en)
*
|
1985-06-04 |
1989-10-25 |
Chugai Pharmaceutical Co Ltd |
A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
|
IL79176A
(en)
*
|
1985-06-20 |
1992-06-21 |
Kirin Amgen Inc |
Process for the recovery of erythropoietin from a fluid
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
JPS63500636A
(ja)
*
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするdna
|
US6004548A
(en)
|
1985-08-23 |
1999-12-21 |
Amgen, Inc. |
Analogs of pluripotent granulocyte colony-stimulating factor
|
US4935350A
(en)
*
|
1985-11-18 |
1990-06-19 |
Amgen |
Materials and methods for controlling plasmid copy number and stability
|
JPS62171696A
(ja)
*
|
1986-01-23 |
1987-07-28 |
Sumitomo Chem Co Ltd |
ヒトエリスロポエチンの製造方法
|
EP0236059B1
(en)
*
|
1986-02-27 |
1994-04-27 |
Snow Brand Milk Products Co. Ltd. |
Preparation of erythropoietin-producing cells and production process of erythropoietin using same
|
DK173067B1
(da)
|
1986-06-27 |
1999-12-13 |
Univ Washington |
Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
|
GR871029B
(en)
|
1986-07-14 |
1987-11-02 |
Genetics Inst |
Novel osteoinductive factors
|
US4954437A
(en)
*
|
1986-09-15 |
1990-09-04 |
Integrated Genetics, Inc. |
Cell encoding recombinant human erythropoietin
|
US5013718A
(en)
*
|
1986-11-21 |
1991-05-07 |
Amgen, Inc. |
Method for treating iron overload using EPO
|
AU1187588A
(en)
*
|
1987-01-15 |
1988-08-10 |
Codon Genetic Engineering Laboratories |
Tandem gene eukaryotic expression vectors
|
US4835260A
(en)
*
|
1987-03-20 |
1989-05-30 |
Genetics Institute, Inc. |
Erythropoietin composition
|
JP2791418B2
(ja)
|
1987-12-02 |
1998-08-27 |
株式会社ミドリ十字 |
異種蛋白質の製造方法、組換えdna、形質転換体
|
DE3923963A1
(de)
*
|
1989-07-20 |
1991-01-31 |
Behringwerke Ag |
Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
|
US6932968B1
(en)
|
1989-07-26 |
2005-08-23 |
Dade Behring Marburg Gmbh |
Erythropoietin (EPO) peptides and antibodies directed against these
|
DE3924746A1
(de)
*
|
1989-07-26 |
1991-01-31 |
Behringwerke Ag |
Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
|
US7217689B1
(en)
|
1989-10-13 |
2007-05-15 |
Amgen Inc. |
Glycosylation analogs of erythropoietin
|
WO1991005867A1
(en)
*
|
1989-10-13 |
1991-05-02 |
Amgen Inc. |
Erythropoietin isoforms
|
DE4115722A1
(de)
*
|
1991-05-14 |
1992-11-19 |
Boehringer Mannheim Gmbh |
Serumfreies medium zur kultivierung von saeugerzellen
|
US5968502A
(en)
*
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US6270989B1
(en)
|
1991-11-05 |
2001-08-07 |
Transkaryotic Therapies, Inc. |
Protein production and delivery
|
PT101031B
(pt)
*
|
1991-11-05 |
2002-07-31 |
Transkaryotic Therapies Inc |
Processo para o fornecimento de proteinas por terapia genetica
|
US5728536A
(en)
*
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
DE69327247T2
(de)
*
|
1992-09-09 |
2000-05-18 |
Nippon Kayaku K.K., Tokio/Tokyo |
Physiologisch aktive substanz nk175203, verfahren zu deren herstellung und pharmazeutische verwendung
|
WO1994024160A2
(en)
*
|
1993-04-21 |
1994-10-27 |
Brigham And Women's Hospital |
Erythropoietin muteins with enhanced activity
|
ZA946122B
(en)
*
|
1993-08-17 |
1995-03-20 |
Amgen Inc |
Erythropoietin analogs
|
US8192955B1
(en)
*
|
1994-01-03 |
2012-06-05 |
Genentech, Inc. |
Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
|
US5888774A
(en)
*
|
1994-12-19 |
1999-03-30 |
Cangene Corporation |
Recombinant DNA molecules and expression vectors for erythropoietin
|
IL118201A
(en)
*
|
1995-05-11 |
2004-12-15 |
Roche Diagnostics Gmbh |
Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
|
NZ310804A
(en)
*
|
1995-06-07 |
1998-10-28 |
Ortho Pharma Corp |
Compounds and peptides that bind to the erythropoietin receptor
|
US5994128A
(en)
|
1995-06-15 |
1999-11-30 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
EP0752474A1
(en)
*
|
1995-07-07 |
1997-01-08 |
Boehringer Mannheim Gmbh |
Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
|
EP0837942A1
(en)
*
|
1995-07-07 |
1998-04-29 |
Boehringer Mannheim Gmbh |
Nucleic acid coding for cmp-n-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
|
DE69724241T2
(de)
|
1996-03-14 |
2004-06-09 |
Genentech, Inc., South San Francisco |
Gdnf-rezeptor und dessen verwendung
|
GB2318352A
(en)
*
|
1996-06-25 |
1998-04-22 |
Dejan Markovic |
Polypeptides mimicking the activity of human erythropoietin
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
EP0975673A2
(en)
*
|
1997-04-21 |
2000-02-02 |
Glycozyme, Inc. |
Determination of recombinant glycosylated proteins and peptides in biological fluids
|
US6475725B1
(en)
|
1997-06-20 |
2002-11-05 |
Baxter Aktiengesellschaft |
Recombinant cell clones having increased stability and methods of making and using the same
|
DE19729769A1
(de)
|
1997-07-11 |
1999-01-14 |
Cardiogene Gentherapeutische S |
Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie
|
US6017876A
(en)
*
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
US6897066B1
(en)
*
|
1997-09-26 |
2005-05-24 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
US7316923B1
(en)
|
1997-09-26 |
2008-01-08 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
JP2001520009A
(ja)
*
|
1997-10-16 |
2001-10-30 |
ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド |
鳥の導入遺伝子についてのマグナム特異的プロモーターを含むベクター
|
EP1489100B1
(en)
|
1997-12-08 |
2016-06-15 |
Merck Patent GmbH |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
WO1999042581A1
(en)
*
|
1998-02-19 |
1999-08-26 |
Eastern Virginia Medical School |
RECOMBINANT ACTIVE HUMAN ZONA PELLUCIDA PROTEIN 3 (hZP3)
|
US7037663B2
(en)
*
|
1998-02-19 |
2006-05-02 |
Eastern Virginia Medical School |
Human zona pellucida protein 3 and uses thereof
|
PT937456E
(pt)
|
1998-02-23 |
2004-10-29 |
Cilag Ag Int |
Dispersao lipossomal de eritropoietina
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
KR100434729B1
(ko)
*
|
1998-03-18 |
2004-11-03 |
주식회사 엘지생명과학 |
천연 추출물을 첨가하여 중국햄스터 난소 유래세포에서 에리스로포이에틴의 생산 증대방법
|
DE1066395T1
(de)
*
|
1998-03-27 |
2002-04-04 |
Marco Boorsma |
Induzierendes alphavirengen- expressionssystem
|
AR019025A1
(es)
|
1998-04-09 |
2001-12-26 |
Roche Diagnostics Gmbh |
Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
|
HUP0101352A3
(en)
*
|
1998-04-15 |
2003-08-28 |
Lexigen Pharmaceuticals Corp L |
Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
|
AU753106B2
(en)
*
|
1998-04-22 |
2002-10-10 |
Cornell Research Foundation Inc. |
Canine erythropoietin gene and recombinant protein
|
US6696411B1
(en)
*
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
US20050181482A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
JP4087563B2
(ja)
*
|
1998-06-15 |
2008-05-21 |
ジーティーシー バイオセラピューティックス インコーポレイテッド |
エリスロポエチン類似体−ヒト血清アルブミン融合物
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
EP1100545A4
(en)
*
|
1998-07-29 |
2002-03-20 |
Invitrogen Corp |
REGULATED EXPRESSION OF RECOMBINANT PROTEINS USING RNA VIRUSES
|
EP0984062A1
(en)
*
|
1998-09-04 |
2000-03-08 |
Cytos Biotechnology AG |
Production of human erythropoietin
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7304150B1
(en)
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
BR9905868A
(pt)
|
1998-11-06 |
2001-01-23 |
Bio Sidus S A |
Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
|
BR9905867A
(pt)
*
|
1998-11-06 |
2001-01-23 |
Bio Sidus S A |
Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
|
BR9917606A
(pt)
|
1998-11-06 |
2002-12-31 |
Bio Sidus S A |
Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
|
DE19857609A1
(de)
|
1998-12-14 |
2000-06-15 |
Hannelore Ehrenreich |
Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
|
US6451346B1
(en)
*
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
DE19905501B4
(de)
|
1999-02-10 |
2005-05-19 |
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie |
Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
US7410941B1
(en)
|
1999-04-13 |
2008-08-12 |
The Kenneth S. Warren Institute, Inc. |
Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
|
US6855544B1
(en)
*
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
US7604960B2
(en)
*
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
US8236561B2
(en)
*
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
US20050164386A1
(en)
*
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
US7297680B2
(en)
*
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
US20050170463A1
(en)
*
|
1999-04-15 |
2005-08-04 |
Abraham Bout |
Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
|
US6555343B1
(en)
|
1999-05-07 |
2003-04-29 |
Genentech Inc. |
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
|
WO2000068376A1
(en)
*
|
1999-05-07 |
2000-11-16 |
Genentech, Inc. |
Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
|
US6831060B2
(en)
|
1999-05-07 |
2004-12-14 |
Genentech, Inc. |
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
|
AT409379B
(de)
|
1999-06-02 |
2002-07-25 |
Baxter Ag |
Medium zur protein- und serumfreien kultivierung von zellen
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US6737519B1
(en)
*
|
1999-07-30 |
2004-05-18 |
Genome Therapeutics Corporation |
Human genes relating to respiratory diseases and obesity
|
JP4793971B2
(ja)
*
|
1999-08-09 |
2011-10-12 |
メルク パテント ゲーエムベーハー |
複合サイトカイン−抗体複合体
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
US6703480B1
(en)
|
1999-11-24 |
2004-03-09 |
Palani Balu |
Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
|
US7527961B2
(en)
*
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
US7521220B2
(en)
*
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
AU1647501A
(en)
|
1999-12-10 |
2001-06-18 |
Cytos Biotechnology Ag |
Replicon based activation of endogenous genes
|
MXPA02007733A
(es)
*
|
2000-02-11 |
2004-09-10 |
Merck Patent Gmbh |
Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos.
|
US20030171267A1
(en)
*
|
2000-04-12 |
2003-09-11 |
Rosen Craig A. |
Albumin fusion proteins
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2001256609A1
(en)
*
|
2000-05-12 |
2001-11-20 |
Cyril John Higgins |
Method of organized retrieval of world-wide web pages
|
CA2412845C
(en)
*
|
2000-06-29 |
2014-07-22 |
Lexigen Pharmaceuticals Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
AU2001273432A1
(en)
*
|
2000-07-13 |
2002-01-30 |
Invitrogen Corporation |
Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7855229B2
(en)
*
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7645898B2
(en)
*
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
EP1326969B1
(en)
|
2000-09-25 |
2009-04-15 |
Genetronics, Inc. |
Improved system for regulation of transgene expression
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
ES2361824T3
(es)
|
2000-12-20 |
2011-06-22 |
F. Hoffmann-La Roche Ag |
Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
|
US6531121B2
(en)
*
|
2000-12-29 |
2003-03-11 |
The Kenneth S. Warren Institute, Inc. |
Protection and enhancement of erythropoietin-responsive cells, tissues and organs
|
US7767643B2
(en)
*
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
KR100399337B1
(ko)
*
|
2001-02-07 |
2003-09-26 |
드림바이오젠 주식회사 |
단백질의 무세포 번역후수식법
|
US7148321B2
(en)
*
|
2001-03-07 |
2006-12-12 |
Emd Lexigen Research Center Corp. |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
DE10112825A1
(de)
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
US6969517B2
(en)
|
2001-05-03 |
2005-11-29 |
Emd Lexigen Research Center Corp. |
Recombinant tumor specific antibody and use thereof
|
AU2002310122A1
(en)
*
|
2001-05-25 |
2002-12-09 |
Human Genome Sciences, Inc. |
Chemokine beta-1 fusion proteins
|
CA2456821A1
(en)
*
|
2001-08-02 |
2003-02-13 |
Trinity Biomedical Technology Corporation |
Human zona pellucida proteins and methods of their use in diagnosing male infertility
|
CA2458261A1
(en)
*
|
2001-08-30 |
2003-03-06 |
Stem Cell Therapeutics Inc. |
Differentiation of neural stem cells and therapeutic use thereof
|
US20030104996A1
(en)
*
|
2001-08-30 |
2003-06-05 |
Tiansheng Li |
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
|
WO2003024472A2
(en)
*
|
2001-09-14 |
2003-03-27 |
Stem Cell Therapeutics Inc. |
Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
|
AU2002325710A1
(en)
*
|
2001-09-18 |
2003-04-01 |
Stem Cell Therapeutics Inc. |
Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
|
MXPA04005190A
(es)
*
|
2001-11-28 |
2005-02-17 |
Sandoz Ag |
Proceso para cultivo de celulas.
|
CN100390282C
(zh)
*
|
2001-12-04 |
2008-05-28 |
默克专利有限公司 |
具有调节的选择性的il-2融合蛋白
|
US20070161608A1
(en)
*
|
2001-12-06 |
2007-07-12 |
Dalton James T |
Selective androgen receptor modulators for treating muscle wasting
|
US8853266B2
(en)
*
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
CA2468957C
(en)
*
|
2001-12-07 |
2011-07-12 |
Crucell Holland B.V. |
Methods of propagation of influenza virus in cell lines over expressing sialyl transferases
|
EP1997829A1
(en)
*
|
2001-12-21 |
2008-12-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2002364587A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2003054172A2
(en)
|
2002-01-17 |
2003-07-03 |
Lonza Biologics Plc. |
Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
US20040009902A1
(en)
*
|
2002-05-13 |
2004-01-15 |
Irving Boime |
CTP extended erythropoietin
|
MXPA05000063A
(es)
*
|
2002-07-01 |
2005-04-08 |
Kenneth S Warren Inst Inc |
Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
|
JP2005532057A
(ja)
|
2002-07-09 |
2005-10-27 |
バクスター・インターナショナル・インコーポレイテッド |
細胞を培養するための動物性タンパク質非含有培地
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
US7368115B2
(en)
*
|
2002-07-31 |
2008-05-06 |
Stem Cell Therapeutics Inc. |
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)
|
JP4326470B2
(ja)
*
|
2002-08-31 |
2009-09-09 |
シージェイチェイルジェダンコーポレーション |
糖鎖化ヒト顆粒球コロニー刺激因子同種体
|
ES2343518T3
(es)
*
|
2002-09-09 |
2010-08-03 |
Hanall Biopharma Co., Ltd. |
Polipeptidos interferon alfa modificados resistentes a proteasas.
|
DE20321793U1
(de)
|
2002-09-11 |
2010-06-02 |
Fresenius Kabi Deutschland Gmbh |
Hydroxyalkylstärke-Derivate
|
EP1681303B1
(en)
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylated polypeptides, especially HASylated erythropoietin
|
WO2004024776A1
(en)
|
2002-09-11 |
2004-03-25 |
Fresenius Kabi Deutschland Gmbh |
Method of producing hydroxyalkyl starch derivatives
|
AU2003273413A1
(en)
|
2002-10-08 |
2004-05-04 |
Fresenius Kabi Deutschland Gmbh |
Pharmaceutically active oligosaccharide conjugates
|
PT1572748E
(pt)
*
|
2002-12-17 |
2010-09-28 |
Merck Patent Gmbh |
Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
|
EP1594530A4
(en)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
HYBRID PROTEINS OF ALBUMIN
|
MXPA05008231A
(es)
*
|
2003-02-03 |
2006-01-17 |
Japan Immuno Inc |
Vector de alta expresion para celulas animales.
|
CA2521979A1
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
US7459152B2
(en)
*
|
2003-04-23 |
2008-12-02 |
Rush University Medical Center |
Erythropoietin administration to improve graft survival
|
WO2004099396A1
(en)
*
|
2003-05-09 |
2004-11-18 |
Crucell Holland B.V. |
Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
|
EA010015B1
(ru)
*
|
2003-05-12 |
2008-06-30 |
Афимакс, Инк. |
Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
|
JP2007530440A
(ja)
*
|
2003-05-12 |
2007-11-01 |
アフィーマックス・インコーポレイテッド |
新規ポリ(エチレングリコール)修飾化合物およびその用途
|
PL1625156T3
(pl)
*
|
2003-05-12 |
2013-03-29 |
Affymax Inc |
Peptydy wiążące się do receptora erytropoetyny
|
SG160224A1
(en)
*
|
2003-05-12 |
2010-04-29 |
Affymax Inc |
Novel peptides that bind to the erythropoietin receptor
|
WO2004104046A1
(en)
*
|
2003-05-23 |
2004-12-02 |
Crucell Holland B.V. |
Production of recombinant igm in per.c6 cells
|
JP4871720B2
(ja)
|
2003-06-10 |
2012-02-08 |
エルジー ライフサイエンス リミテッド |
血清アルブミンを含まない、安定なヒトエリスロポエチン水溶液
|
EP2216415B2
(en)
*
|
2003-08-01 |
2017-01-04 |
Life Technologies Corporation |
Methods for preparing short RNA molecules
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
MXPA06003234A
(es)
|
2003-09-29 |
2006-06-08 |
Warren Pharmaceuticals Inc |
Citosinas protectoras de los tejidos para el tratamiento y prevencion de la sepsis y la formacion de adhesiones.
|
US20060003008A1
(en)
|
2003-12-30 |
2006-01-05 |
Gibson John W |
Polymeric devices for controlled release of active agents
|
DK2233150T3
(en)
|
2003-12-30 |
2016-12-12 |
Augustinus Bader |
Erythropoietin for use in the treatment of wounds or transplantation of cells
|
KR20060124656A
(ko)
*
|
2003-12-31 |
2006-12-05 |
메르크 파텐트 게엠베하 |
개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질
|
DE102004063927A1
(de)
|
2004-01-23 |
2005-12-15 |
Epoplus Gmbh Co.Kg |
Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
|
WO2005077404A1
(en)
*
|
2004-02-13 |
2005-08-25 |
Stem Cell Therapeutics Corp. |
Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
|
US7255288B2
(en)
*
|
2004-03-08 |
2007-08-14 |
Wan Shan Chan |
Aroma therapy for fountain
|
CN1946742A
(zh)
|
2004-03-11 |
2007-04-11 |
弗雷泽纽斯卡比德国有限公司 |
通过还原氨基化制备的羟烷基淀粉和蛋白质的偶联物
|
CN102302787A
(zh)
|
2004-03-11 |
2012-01-04 |
费森尤斯卡比德国有限公司 |
羟烷基淀粉和蛋白质的接合物
|
US7588745B2
(en)
*
|
2004-04-13 |
2009-09-15 |
Si Options, Llc |
Silicon-containing products
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
US20110237664A1
(en)
*
|
2004-06-07 |
2011-09-29 |
Dalton James T |
Selective androgen receptor modulators for treating diabetes
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US20060094104A1
(en)
|
2004-10-29 |
2006-05-04 |
Leopold Grillberger |
Animal protein-free media for cultivation of cells
|
MX2007005777A
(es)
*
|
2004-11-11 |
2007-07-20 |
Affymax Inc |
Peptidos novedosos que se unen al receptor de eritropoietina.
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
WO2006061853A2
(en)
*
|
2004-12-10 |
2006-06-15 |
Serum Institute Of India Limited |
Novel erythropoietic compounds and a process for producing erythropoietic compounds
|
EP1848461A2
(en)
*
|
2005-02-16 |
2007-10-31 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
*
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
EP2425715B1
(en)
|
2005-08-31 |
2014-03-05 |
University of Tennessee Research Foundation |
Treating symptoms of renal disease with selective androgen receptor modulators (SARM)
|
EP1762250A1
(en)
|
2005-09-12 |
2007-03-14 |
Fresenius Kabi Deutschland GmbH |
Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
|
CA2664629A1
(en)
|
2005-09-27 |
2007-04-05 |
Christopher Gregg |
Oligodendrocyte precursor cell proliferation regulated by prolactin
|
US9388382B2
(en)
*
|
2005-10-05 |
2016-07-12 |
The Board Of Trustees Of The University Of Illinois |
Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
|
EP1966237A2
(en)
*
|
2005-11-24 |
2008-09-10 |
Laboratoires Serono SA |
Erythropoietin polypeptides and uses thereof
|
ES2913277T3
(es)
|
2005-12-08 |
2022-06-01 |
Amgen Inc |
Producción mejorada de glicoproteínas utilizando manganeso
|
CA2633306A1
(en)
|
2006-01-04 |
2007-07-12 |
Baxter International Inc. |
Oligopeptide-free cell culture media
|
DE102006004008A1
(de)
|
2006-01-27 |
2007-08-02 |
Hannelore Prof. Dr. Dr. Ehrenreich |
Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
|
US7625564B2
(en)
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
US8143220B2
(en)
*
|
2006-03-17 |
2012-03-27 |
Stem Cell Therapeutics Corp. |
Dosing regimens for neural stem cell proliferating agents and differentiating agents for the treatment of neurological disorders
|
US8546329B2
(en)
|
2006-03-22 |
2013-10-01 |
Chugai Seiyaku Kabushiki Kaisha |
Erythropoietin solution preparation
|
CN101062407A
(zh)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
促红细胞生成素在预防或治疗视网膜损伤中的用途
|
MX2009000385A
(es)
|
2006-07-12 |
2009-04-06 |
Univ Tennessee Res Foundation |
Acil-anilidas sustituidas y metodos de uso de las mismas.
|
CA2659990C
(en)
|
2006-08-04 |
2016-03-22 |
Prolong Pharmaceuticals, Inc. |
Polyethylene glycol erythropoietin conjugates
|
WO2008023725A1
(fr)
|
2006-08-22 |
2008-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Agent préventif et/ou thérapeutique pour une neuropathie périphérique
|
ES2581765T3
(es)
|
2006-08-24 |
2016-09-07 |
University Of Tennessee Research Foundation |
Acilanilidas sustituidas y métodos de uso de las mismas
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
KR101449587B1
(ko)
*
|
2006-09-14 |
2014-10-10 |
메드제닉스 메디칼 이스라엘 리미티드 |
장기 지속형 약물 제형
|
US8835163B2
(en)
*
|
2006-10-18 |
2014-09-16 |
The Board Of Trustees Of The University Of Illinois |
Embryonic-like stem cells derived from adult human peripheral blood and methods of use
|
CN101678079B
(zh)
|
2006-11-28 |
2013-12-25 |
韩诺生物制约株式会社 |
修饰的促红细胞生成素多肽及其治疗用途
|
US20110105734A1
(en)
*
|
2006-12-06 |
2011-05-05 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of human erythropoietin
|
US20100115638A1
(en)
*
|
2006-12-19 |
2010-05-06 |
Amina Abina |
Method for inhibiting the expression of endogenous erythropoietin (epo)
|
AU2008214386B2
(en)
*
|
2007-02-02 |
2013-09-19 |
Amgen Inc |
Hepcidin and hepcidin antibodies
|
AR065613A1
(es)
|
2007-03-09 |
2009-06-17 |
Chugai Pharmaceutical Co Ltd |
Agentes de proteccion para organos transplantados
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
WO2008151841A2
(en)
|
2007-06-15 |
2008-12-18 |
University Of Zurich |
Treatment for alzheimer' s disease
|
WO2009010107A1
(en)
|
2007-07-19 |
2009-01-22 |
Hannelore Ehrenreich |
Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
|
US8067548B2
(en)
*
|
2007-07-26 |
2011-11-29 |
Novagen Holding Corporation |
Fusion proteins having mutated immunoglobulin hinge region
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
AU2008304111B2
(en)
*
|
2007-09-27 |
2014-04-24 |
Amgen Inc. |
Pharmaceutical formulations
|
EP3381445B1
(en)
|
2007-11-15 |
2023-10-25 |
Amgen Inc. |
Aqueous formulation of antibody stablised by antioxidants for parenteral administration
|
EP2070950A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Hydroxyalkyl starch derivatives and process for their preparation
|
EP2803675A3
(en)
|
2008-01-25 |
2014-12-24 |
Amgen, Inc |
Ferroportin antibodies and methods of use
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
EP2095829A1
(en)
|
2008-02-27 |
2009-09-02 |
LEK Pharmaceuticals D.D. |
Selenium containing modifying agents and conjugates
|
US8653249B2
(en)
*
|
2008-02-27 |
2014-02-18 |
Fuso Pharmaceutical Industries, Ltd. |
Expression vector for mass production of foreign gene-derived protein using animal cell and use thereof
|
MX2010011717A
(es)
|
2008-05-01 |
2010-11-30 |
Amgen Inc |
Anticuerpos anti-hepcidina y metodos de uso.
|
DE102008002210A1
(de)
*
|
2008-06-04 |
2009-12-10 |
Evonik Degussa Gmbh |
Verfahren zur fermentativen Herstellung von Erythropoietin
|
DE102008002209A1
(de)
|
2008-06-04 |
2009-12-10 |
Evonik Degussa Gmbh |
Verfahren zur Aufreinigung von Erythropoietin
|
US8003689B2
(en)
*
|
2008-06-20 |
2011-08-23 |
Gtx, Inc. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
WO2010034442A1
(en)
|
2008-09-23 |
2010-04-01 |
F. Hoffmann-La Roche Ag |
Purification of erythropoietin
|
UA106731C2
(uk)
|
2008-09-26 |
2014-10-10 |
Амбркс, Інк. |
Модифіковані поліпептиди еритропоетину тварин та їх застосування
|
ES2766257T3
(es)
|
2008-11-13 |
2020-06-12 |
Massachusetts Gen Hospital |
Métodos y composiciones para regular la homeostasis del hierro mediante la modulación de bmp-6
|
DE102008054716A1
(de)
|
2008-12-16 |
2010-06-17 |
Evonik Degussa Gmbh |
Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
|
ES2552325T3
(es)
|
2008-12-22 |
2015-11-27 |
National University Corporation Hokkaido University |
Vector de expresión para producción a gran escala de proteína derivada de genes foráneos usando células animales, y uso del mismo
|
US20100272816A1
(en)
|
2009-04-27 |
2010-10-28 |
Wolfgang Rudinger |
Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
|
HRP20212024T1
(hr)
|
2009-05-02 |
2022-04-01 |
Genzyme Corporation |
Genska terapija za neurodegenerativne poremećaje
|
AU2010297530B2
(en)
|
2009-09-23 |
2013-12-19 |
Ratiopharm Gmbh |
Process for the purification of recombinant human erythropoietin (EPO), EPO thus purified and pharmaceutical compositions comprising same
|
WO2011050333A1
(en)
|
2009-10-23 |
2011-04-28 |
Amgen Inc. |
Vial adapter and system
|
WO2011156373A1
(en)
|
2010-06-07 |
2011-12-15 |
Amgen Inc. |
Drug delivery device
|
CN103260649A
(zh)
|
2010-06-15 |
2013-08-21 |
迈德詹尼克斯医疗以色列有限公司 |
长效药物制剂
|
EA032917B1
(ru)
|
2010-09-28 |
2019-08-30 |
Амилин Фармасьютикалс, Ллк |
Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
|
AU2012236573B2
(en)
|
2011-03-31 |
2016-06-02 |
Amgen Inc. |
Vial adapter and system
|
EP2699293B8
(en)
|
2011-04-20 |
2022-07-20 |
Amgen Inc. |
Autoinjector apparatus
|
US9987428B2
(en)
|
2011-10-14 |
2018-06-05 |
Amgen Inc. |
Injector and method of assembly
|
KR101443257B1
(ko)
|
2011-10-18 |
2014-09-19 |
주식회사 종근당 |
낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
|
EP2771294B1
(en)
|
2011-10-25 |
2017-12-13 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
PT2872482T
(pt)
|
2012-07-13 |
2020-09-22 |
Oncternal Therapeutics Inc |
Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US9650411B2
(en)
|
2012-08-07 |
2017-05-16 |
Kyowa Hakko Kirin Co., Ltd. |
Method of purifying protein
|
CN104822826B
(zh)
|
2012-10-15 |
2019-04-30 |
百时美施贵宝公司 |
用于蛋白产生的哺乳动物细胞培养过程
|
WO2014081780A1
(en)
|
2012-11-21 |
2014-05-30 |
Amgen Inc. |
Drug delivery device
|
EP2970351B1
(en)
*
|
2013-03-14 |
2017-09-13 |
Translate Bio, Inc. |
Ribonucleic acids with 4'-thio-modified nucleotides and related methods
|
EP2968760B1
(en)
|
2013-03-15 |
2024-01-03 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
US10492990B2
(en)
|
2013-03-15 |
2019-12-03 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
US10066001B2
(en)
|
2013-03-15 |
2018-09-04 |
Apotex Inc. |
Enhanced liquid formulation stability of erythropoietin alpha through purification processing
|
JP6463331B2
(ja)
|
2013-03-15 |
2019-01-30 |
イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー |
抗ヘプシジン抗体およびその使用
|
WO2014149357A1
(en)
|
2013-03-22 |
2014-09-25 |
Amgen Inc. |
Injector and method of assembly
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
KR102118240B1
(ko)
|
2013-08-20 |
2020-06-03 |
레크 파마슈티칼스 디.디. |
폴리펩티드의 α-아미드화 및/또는 C-말단 아미노산 분열의 제어를 위한 세포 배양 매질 및 방법
|
US11097055B2
(en)
|
2013-10-24 |
2021-08-24 |
Amgen Inc. |
Injector and method of assembly
|
EP3957345A1
(en)
|
2013-10-24 |
2022-02-23 |
Amgen, Inc |
Drug delivery system with temperature-sensitive control
|
WO2015059701A1
(en)
|
2013-10-24 |
2015-04-30 |
Medgenics Medical Israel Ltd. |
Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
|
WO2015119906A1
(en)
|
2014-02-05 |
2015-08-13 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
SG11201609219QA
(en)
|
2014-05-07 |
2016-12-29 |
Amgen Inc |
Autoinjector with shock reducing elements
|
BR112016027778A2
(pt)
|
2014-05-30 |
2017-08-15 |
Pfizer |
Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
|
US10646652B2
(en)
|
2014-06-03 |
2020-05-12 |
Amgen Inc. |
Controllable drug delivery system and method of use
|
CA2961917A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
MX2021014323A
(es)
|
2014-10-14 |
2023-02-02 |
Amgen Inc |
Dispositivo de inyección de fármaco con indicadores visuales y audibles.
|
JP6716566B2
(ja)
|
2014-12-19 |
2020-07-01 |
アムジエン・インコーポレーテツド |
近接センサ付き薬物送達装置
|
WO2016100055A1
(en)
|
2014-12-19 |
2016-06-23 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
MX2017010466A
(es)
|
2015-02-17 |
2018-06-06 |
Amgen Inc |
Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas.
|
WO2016138434A1
(en)
|
2015-02-27 |
2016-09-01 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
WO2017068051A1
(en)
|
2015-10-21 |
2017-04-27 |
Lek Pharmaceuticals D.D. |
Peg-based dendron and process for producing the same
|
US11351308B2
(en)
|
2015-12-09 |
2022-06-07 |
Amgen Inc. |
Auto-injector with signaling cap
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
ES2814287T3
(es)
|
2016-03-15 |
2021-03-26 |
Amgen Inc |
Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
MX2018013616A
(es)
|
2016-05-13 |
2019-02-21 |
Amgen Inc |
Montaje de cubierta protectora de vial.
|
WO2017200989A1
(en)
|
2016-05-16 |
2017-11-23 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
WO2017209899A1
(en)
|
2016-06-03 |
2017-12-07 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
EP3478342A1
(en)
|
2016-07-01 |
2019-05-08 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
WO2018034784A1
(en)
|
2016-08-17 |
2018-02-22 |
Amgen Inc. |
Drug delivery device with placement detection
|
EP3532127A1
(en)
|
2016-10-25 |
2019-09-04 |
Amgen Inc. |
On-body injector
|
JP2020503976A
(ja)
|
2017-01-17 |
2020-02-06 |
アムジエン・インコーポレーテツド |
注入デバイスならびに関連する使用および組立方法
|
AU2018220538B2
(en)
|
2017-02-17 |
2023-12-14 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
JP7280189B2
(ja)
|
2017-02-17 |
2023-05-23 |
アムジエン・インコーポレーテツド |
薬物送達装置用の挿入機構
|
JP2020508803A
(ja)
|
2017-03-06 |
2020-03-26 |
アムジエン・インコーポレーテツド |
作動防止特徴部を備える薬物送達デバイス
|
EP3592402A1
(en)
|
2017-03-07 |
2020-01-15 |
Amgen Inc. |
Needle insertion by overpressure
|
IL303449B2
(en)
|
2017-03-09 |
2024-08-01 |
Amgen Inc |
Insertion mechanism for a drug delivery device
|
JP2020511499A
(ja)
|
2017-03-20 |
2020-04-16 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
|
SI3600491T1
(sl)
|
2017-03-28 |
2023-11-30 |
Amgen Inc. |
Sistem in postopek za sestavljanja droga bata in brizge
|
AU2018282077B2
(en)
|
2017-06-08 |
2023-11-23 |
Amgen Inc. |
Torque driven drug delivery device
|
WO2018226515A1
(en)
|
2017-06-08 |
2018-12-13 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
KR102268647B1
(ko)
|
2017-06-12 |
2021-06-23 |
한국코러스 주식회사 |
안정성이 향상된 에리스로포이에틴 조성물 및 이의 제조방법
|
EP3641857A1
(en)
|
2017-06-22 |
2020-04-29 |
Amgen Inc. |
Device activation impact/shock reduction
|
MX2019015479A
(es)
|
2017-06-23 |
2020-02-20 |
Amgen Inc |
Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador.
|
JP7408398B2
(ja)
|
2017-07-14 |
2024-01-05 |
アムジエン・インコーポレーテツド |
二重ねじりばねシステムを有する針挿入後退システム
|
EP3655063A1
(en)
|
2017-07-21 |
2020-05-27 |
Amgen Inc. |
Gas permeable sealing member for drug container and methods of assembly
|
WO2019022951A1
(en)
|
2017-07-25 |
2019-01-31 |
Amgen Inc. |
DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
|
EP3658206A1
(en)
|
2017-07-25 |
2020-06-03 |
Amgen Inc. |
Drug delivery device with container access system and related method of assembly
|
US20200164155A1
(en)
|
2017-08-09 |
2020-05-28 |
Amgen Inc. |
Hydraulic-pneumatic pressurized chamber drug delivery system
|
WO2019036181A1
(en)
|
2017-08-18 |
2019-02-21 |
Amgen Inc. |
BODY INJECTOR WITH STERILE ADHESIVE PATCH
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
ES2939292T3
(es)
|
2017-10-04 |
2023-04-20 |
Amgen Inc |
Adaptador de flujo para dispositivo de administración de fármacos
|
WO2019070552A1
(en)
|
2017-10-06 |
2019-04-11 |
Amgen Inc. |
DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
|
IL273323B1
(en)
|
2017-10-09 |
2024-06-01 |
Amgen Inc |
Drug delivery device with drive assembly and related assembly method
|
EP3703779A1
(en)
|
2017-11-03 |
2020-09-09 |
Amgen Inc. |
Systems and approaches for sterilizing a drug delivery device
|
US20200261648A1
(en)
|
2017-11-06 |
2020-08-20 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
US12053618B2
(en)
|
2017-11-06 |
2024-08-06 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
EP3706826A1
(en)
|
2017-11-10 |
2020-09-16 |
Amgen Inc. |
Plungers for drug delivery devices
|
CA3084486A1
(en)
|
2017-11-16 |
2019-05-23 |
Amgen Inc. |
Autoinjector with stall and end point detection
|
CA3079540A1
(en)
|
2017-11-16 |
2019-05-23 |
Amgen Inc. |
Door latch mechanism for drug delivery device
|
US11781146B2
(en)
|
2018-05-24 |
2023-10-10 |
National University Corporation Hokkaido University |
Vector including a translation-impaired dihydrofolate reductase gene cassette and ubiquitously acting chromatin opening element
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
US20210228815A1
(en)
|
2018-07-24 |
2021-07-29 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
WO2020023220A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
|
CN112469454B
(zh)
|
2018-07-24 |
2024-01-26 |
安进公司 |
用于施用药物的输送装置
|
MX2021000749A
(es)
|
2018-07-24 |
2021-03-29 |
Amgen Inc |
Dispositivos de suministro para administrar farmacos.
|
WO2020028009A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
US20210346601A1
(en)
|
2018-09-24 |
2021-11-11 |
Amgen Inc. |
Interventional dosing systems and methods
|
AU2019350660A1
(en)
|
2018-09-28 |
2021-03-18 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
CA3110529A1
(en)
|
2018-10-02 |
2020-04-09 |
Amgen Inc. |
Injection systems for drug delivery with internal force transmission
|
AU2019355979A1
(en)
|
2018-10-05 |
2021-03-18 |
Amgen Inc. |
Drug delivery device having dose indicator
|
EA202191038A1
(ru)
|
2018-10-15 |
2021-07-06 |
Эмджен Инк. |
Способ платформенной сборки для устройства доставки лекарственного средства
|
CA3112355A1
(en)
|
2018-10-15 |
2020-04-23 |
Amgen Inc. |
Drug delivery device having damping mechanism
|
MA54048A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
|
EP3873563A1
(en)
|
2018-11-01 |
2021-09-08 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
AU2020263289A1
(en)
|
2019-04-24 |
2021-09-16 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
CA3148261A1
(en)
|
2019-08-23 |
2021-03-04 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
US20240208680A1
(en)
|
2021-05-21 |
2024-06-27 |
Amgen Inc. |
Method of optimizing a filling recipe for a drug container
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023209074A1
(en)
|
2022-04-28 |
2023-11-02 |
Institut National de la Santé et de la Recherche Médicale |
Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
|
WO2024094457A1
(en)
|
2022-11-02 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Method for producing glycoprotein compositions
|